Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
17 June 2025 | Story Tshepo Tsotetsi | Photo Supplied
Dr Herkulaas Combrink
Dr Herkulaas Combrink is representing UFS in a new international research project that aims to improve how evidence is used in public health policymaking.

Dr Herkulaas Combrink, a senior lecturer in the Faculty of Economic and Management Sciences (EMS) at the University of the Free State (UFS), is representing the university in a new international research project that aims to improve how evidence is used in public health policymaking.

Dr Combrink, who is also a co-director of the Interdisciplinary Centre for Digital Futures (ICDF), has been selected as one of the principal investigators in a newly funded project supported by the UK’s International Science Partnerships Fund under the Evidence-Informed Policymaking Programme. Running from April 2025 to March 2026, the project – titled Integrating Evidence for Contextualised Public Health Policy: Lessons from South Africa – explores how different types of evidence can be used more effectively in shaping public health policy. The international collaboration includes researchers from the Centre for Philosophy of Epidemiology, Medicine and Public Health, which is a collaboration between Durham University and the University of Johannesburg; as well as Durham’s Centre for Humanities Engaging Science and Society.

 

From the Free State to global impact

For Dr Combrink, being part of this collaboration highlights the important work being done in the faculty and ICDF that is reaching beyond borders. 

“It’s important to showcase the impact we are making from the Free State that leads to global outcomes,” he said.

The project aims to evaluate an evidence mapping framework to determine how model-based projections and social listening reports can be more effectively integrated and contextualised for policymaking.

“These are two very different data types,” he explained. “The value lies in demonstrating how to apply the framework to different contexts for evidence-based mapping.”

Dr Combrink brings extensive expertise to the team, having worked on both disease modelling and risk communication during South Africa’s COVID-19 response. He was involved in national and provincial social listening initiatives, and used high-frequency social media data to track the spread of misinformation, often referred to as the ‘infodemic.’ 

“We’ve built up enough data within ICDF and EMS to support this study,” he noted.

The goal is not just theoretical. A key outcome of the project is engaging directly with policymakers to refine modelling and risk communication strategies for future pandemics. 

“This will help us to engage with the various departments of health to assist with improving modelling and risk communication work for better social behavioural change,” he explained.

According to Prof Brownhilder Neneh, Vice-Dean for Research and Internationalisation in the EMS faculty, the project reflects the faculty’s growing global presence. 

“Dr Combrink’s participation is a testament to the calibre of scholarship within the faculty,” she said. “It positions EMS as a key contributor to shaping policy and practice with societal impact.”

She added that the collaboration aligns well with the faculty’s vision for global partnerships that are rooted in local relevance.

“By focusing on contextualised evidence for policymaking, this project reflects our commitment to relevance, engagement and global partnership,” she said.

 

What comes next

Over the project’s 12-month timeline, the team will deliver:

• a case study analysis of modelling and social listening during South Africa’s COVID-19 response;
• an extended evidence mapping framework tailored to diverse evidence types;
• policy briefs and practical tools for public health practitioners; and
• a hybrid international workshop in late 2025 bringing together researchers, policymakers and health professionals to test and refine these outputs.

News Archive

Link between champagne bubbles and the UFS?
2012-11-16

Prof. Lodewyk Kock with an example of a front page of the publication FEMS Yeast Research, as adapted by F. Belliard, FEMS Central Office.
Photo: Leatitia Pienaar
15 November 2012

What is the link between the bubbles in champagne and breakthrough research being done at the Mayo Clinic in America? Nano research being done at our university.

Prof. Lodewyk Kock of Biotechnology says a human being consists of millions of minute cells that are invisible to the eye. The nano technology team at the UFS have developed a technique that allows researchers to look into such a cell, as well as other microorganisms. In this way, they can get an idea of what the cell’s “insides” look like.

The UFS team – consisting of Profs. Kock, Hendrik Swart (Physics), Pieter van Wyk (Centre for Microscopy), as well as Dr Chantel Swart (Biotechnology), Dr Carlien Pohl (Biotechnology) and Liza Coetsee (Physics) – were amazed to see that the inside of cells consist of a maze of small tunnels or blisters. Each tunnel is about 100 and more nanometres in diameter – about one ten thousandth of a millimetre – that weaves through the cells in a maze.

It was also found that these tunnels are the “lungs” of the cells. Academics doing research on yeast have had to sit up and take notice of the research being done at the UFS – to the extent that these “lungs” will appear on the front page of the highly acclaimed FEMS Yeast Research for all of 2013.

The Mayo Clinic, in particular, now wants to work with the UFS to study cancer cells in more detail in order to fight this disease, says Prof. Kock. The National Cancer Institute of America has also shown interest. This new nano technology for biology can assist in the study and development of nano medicine that can be used in the treatment of cancer and other life threatening diseases. Nano medicine uses nano metal participles that are up to one billionth of a metre in size.

Prof. Kock says laboratory tests indicate that nano medicine can improve the efficacy of anti-cancer medicine, which makes the treatment less toxic. “According to the Mayo Clinic team, nano particles are considered as a gold cartridge which is being fired directly at a cancer tumour. This is compared to fine shot that spreads through the body and also attacks healthy cells.”

“This accuracy implies that the chemotherapy dose can be lowered with fewer side effects. The Mayo Clinic found that one-tenth of the normal dosage is more effective against pancreas cancer in this way than the full dosage with a linkage to nano particles. According to the clinic, this nano medicine could also delay the spread of cancer,” says Prof. Kock.

The nano particles are used as messengers that convey anti-cancer treatment to cancer cells, where it then selectively kills the cancer cells. The transport and transfer of these medicines with regard to gold nano particles can be traced with the UFS’s nano technology to collect more information, especially where it works on the cell.

“With the new nano technology of the UFS, it is possible to do nano surgery on the cells by slicing the cells in nanometre thin slices while the working of the nano medicine is studied. In this way, it can be established if the nano medicine penetrates the cells or if it is only associated with the tiny tunnels,” says Prof. Kock.

And in champagne the small “lungs” are responsible for the bubbles. The same applies to beer and with this discovery a whole new reach field opens for scientists.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept